Differentiating Care In Early Arthritis By Prognosis And Risk Stratification: A Therapeutic Algorithm To Improve Outcome and Reduce Costs

Hans-Eckhard Langer, Stephanie Langer

Background

New therapies have improved the outcome of rheumatoid arthritis and related conditions dramatically. On the other hand limited resources require a well directed assignment of biological agents and other cost-intensive treatments. For a managed care programme in our early arthritis clinic we developed a therapeutic algorithm that differentiates defined treatment strategies using a prognostic score. By periodical re-grading and re-staging the therapy is adjusted with the treatment objectives clinical remission, unimpaired functional capacity and inhibition of radiographic progression.

Methods

In the early arthritis cohort (disease duration < 2 years; mean disease duration at entry 17,5 months, median 12,0 months, age 57,2 years, median 59,2 years, 86% female) an initial appraisal of prognosis resulted from a modified Visser-score (erosion score, Visser et al. 2002, plus shared epitopes and MR-findings as additional prognostic markers). Final classification was performed after consideration of clinical data (DAS-28, HAQ). For a following treatment period of 3 months patients were assigned to one of four risk groups (low (< 25%) risk, moderate (25-50%) risk, high (50-75%) risk and very high (75-100%) risk for developing erosions). Treatment modalities (e.g. DMARDs, steroids), intensity of care (inpatient, outpatient; frequency and duration of physiotherapy, occupational therapy etc) and frequency of control visits were ascertained according to the particular risk group. If the therapeutic objectives (DAS28 < 3.2, HAQ < 1.0, halt of radiographic progression) were achieved at periodical assessments every 3 months (x-rays every 12 months) and re-evaluation of prognosis resulted in the same risk group, current therapy was continued unchanged within the treatment corridor of that group. In all other cases therapy was modified and adjusted to the new risk group.

Results

150 patients with early arthritis were recruited from July 2005 to December 2007. For the present, follow-up data over 12 months were available in 85 patients and over 24 months in 32 patients. Over these periods the intended objectives could be achieved. The majority of patients were in clinical remission after 12 months (DAS28 <3.2: 55/85 (65%), DAS28 < 2.6: 39/85 (46%)) and after 24 months (DAS28 < 3.2: 25/32 (76%), DAS28 < 2.6: 19/32 (59%)) despite different treatment modalities with different assignment of resources (DMARDs at 12 months: no DMARDs 23/85 (27%), conventional mono 39/85 (46%), conventional combi 9/85 (11%), biological 11/85 (13%) (1 mono, 10 combi). Radiographic progression was observed in 2/58 patients at 12 months (3,5%) and 2/24 patients at 24 months (8%). Conversely, at 24 months healing phenomena with regression of erosions were seen in 3 patients with erosions at entry.


Key references


Hazes JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002 Feb;46(2):357-65


Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Järvinen P, Hakola M, Piirainen H, Ahonen J, Pälvimäki I, Forsberg S, Koota K, Friman C, ivision of Rheumatology, Turku University Central Hospital, Finland. timo.mottonen@tyks.fi Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999 May 8:353(9164):1568-73

/ries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Rondav HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005 Nov;52(11):3381-90 Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the


TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9 Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort study group: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443-9








Fürstenwall 99, D-40217 Düsseldorf, E-Mail: Dr.Langer@rheuma-online.de, WWW: www.rheuma-online.de




Outcome at 24 months: function



Acknowledgements: the model was developed in cooperations of the German compulsory health insurance (DAK, Deutsche Angestellten Krankenkasse, HMK, Hamburg-Münchner Krankenkasse)

Schwerpunkt für Rheumatologie, klinische Immunologie und Osteologie am Evangelischen Krankenhaus Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Germany





Steroids

Prednisolon > 5 mg

Bone density measurement

Steroids

> 5 mg

steroids (exception)

Bone density


Prednisolon (normal case)

x250 mg Ca+-L.000 E Vit D3


< 2.0: Bisphos-

no steroids (exception)

Treatment algorithm in early arthritis: medical therapy



Treatment algorithm in early arthritis: medical therapy




$\mathsf{THU0120}$

Conclusion

This managed care project combines five principles to achieve better outcomes for early arthritis patients:

- Stratification of therapy depending on prediction criteria (modified Visser-Score)
- Aiming for clinical remission (Fin-RACo)
- DAS-related modification of antirheumatic therapy (BeST)
- Tight control (TICORA)
- Tailoring of therapy to the individual patient using a predefined algorithm (CAMERA)

The results suggest that this approach may result in good clinical outcomes and save resources by well directed assignment of therapy.



Prediction for erosive arthritis (Visser-Score)

Diagnostic criteria (model 1, erosive vs. non-erosive arthritis) for a given persistent arthritis

		-	
		Odds ratio	Score
Duration of symptoms \geq 6 weeks, but < 6 months \geq 6 months		0.96 1.44	0 0
Morning stiffness \geq 1 hour		1.96	1
Arthritis in \geq 3 regions		1.73	1
Bilateral pain at lateral compression of MTP joints		3.78	2
IgM rheumatoid factor \geq 5 IU		2.99	2
Anti-CCP <u>></u> 92 IU		4.58	3
Erosions in x-rays of hands or feet		7	7
Result			
Modification: positive RF-ELISA (IgG-, IgA, IgA-RF) in "seronegative" patients			
Total score	probability for erosions		
0-1	<u><</u> 25%		
2-3	<u><</u> 50%		
4-5	<u><</u> 75%		
6-7	> 75-100%		

Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW: How to diagnose rheumatoid arthritis early. A prediction mode for persistent (erosive) arthritis. Arthritis Rheum 46 (2002), pp 357-365